Drug-induced prolongation of the QT interval: why the regulatory concern?

Fundam Clin Pharmacol. 2002 Apr;16(2):119-24. doi: 10.1046/j.1472-8206.2002.00082.x.
No abstract available

MeSH terms

  • Anti-Arrhythmia Agents / adverse effects
  • Drug Interactions
  • Drug-Related Side Effects and Adverse Reactions*
  • Guidelines as Topic
  • Humans
  • Long QT Syndrome / chemically induced*
  • Pharmacogenetics
  • Torsades de Pointes / chemically induced

Substances

  • Anti-Arrhythmia Agents